Subthreshold micropulse laser adjuvant to bevacizumab versus bevacizumab monotherapy in treating diabetic macular edema: one- year- follow-up.
anti-VEGF
bevacizumab
diabetic macular edema
micropulse laser
subthreshold laser
Journal
Therapeutic advances in ophthalmology
ISSN: 2515-8414
Titre abrégé: Ther Adv Ophthalmol
Pays: United States
ID NLM: 101728805
Informations de publication
Date de publication:
Historique:
received:
30
04
2021
accepted:
03
08
2021
entrez:
9
9
2021
pubmed:
10
9
2021
medline:
10
9
2021
Statut:
epublish
Résumé
To compare the therapeutic impact of combining intravitreal injections of bevacizumab (IVB) with micropulse laser (MPL) in central diffuse diabetic macular edema (DME) versus IVB monotherapy during 12 months follow-up. We conducted a retrospective comparative study of 98 treatment-naive eyes (63 patients) with central diffuse DME. The first group of patients (IVB + MPL group, In IVB + MPL group, baseline BCVA improvement was not significant at 4 and 8 months ( Combining intravitreal injections of bevacizumab and MPL in the treatment of DME is effective and safe. This protocol may decrease the number of IVB and its frequency. It offers the advantage of lasting therapeutic response with fewer recurrences.
Identifiants
pubmed: 34497974
doi: 10.1177/25158414211040887
pii: 10.1177_25158414211040887
pmc: PMC8419546
doi:
Types de publication
Journal Article
Langues
eng
Pagination
25158414211040887Informations de copyright
© The Author(s), 2021.
Déclaration de conflit d'intérêts
Conflict of interest statement: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Références
Trials. 2019 Feb 12;20(1):122
pubmed: 30755274
Arch Ophthalmol. 1991 Nov;109(11):1549-51
pubmed: 1755735
BMC Ophthalmol. 2018 Jul 11;18(1):168
pubmed: 29996798
Ophthalmology. 2008 Sep;115(9):1447-9, 1449.e1-10
pubmed: 18662829
Sci Rep. 2019 May 20;9(1):7585
pubmed: 31110222
JAMA. 2015 Nov 24;314(20):2137-2146
pubmed: 26565927
Ophthalmology. 2012 Apr;119(4):789-801
pubmed: 22330964
Adv Ther. 2017 Jul;34(7):1528-1555
pubmed: 28540655
Jpn J Ophthalmol. 2015 Jan;59(1):21-8
pubmed: 25392274
Semin Ophthalmol. 2004 Mar-Jun;19(1-2):62-8
pubmed: 15590536
Dev Ophthalmol. 2017;58:102-138
pubmed: 28351052
Retina. 2012 Feb;32(2):375-86
pubmed: 21971077
Retina. 2010 Jun;30(6):908-16
pubmed: 20168272
Curr Opin Ophthalmol. 2017 Nov;28(6):636-643
pubmed: 28837425
Arch Ophthalmol. 1985 Dec;103(12):1796-806
pubmed: 2866759
Retina. 2014 Oct;34(10):2010-20
pubmed: 24837050
Acta Ophthalmol. 2019 Jun;97(4):e559-e567
pubmed: 30585429
Ophthalmology. 2015 Jul;122(7):1402-15
pubmed: 25983216
Ophthalmology. 2016 Jun;123(6):1351-9
pubmed: 26935357
Graefes Arch Clin Exp Ophthalmol. 2019 Jul;257(7):1373-1380
pubmed: 31127381
Eye (Lond). 2010 May;24(5):784-8
pubmed: 19680274
Semin Ophthalmol. 2016;31(1-2):30-9
pubmed: 26959127
Retina. 2012 Sep;32(8):1592-600
pubmed: 22466485
N Engl J Med. 2012 Mar 29;366(13):1227-39
pubmed: 22455417
Am J Ophthalmol. 1992 Jun 15;113(6):652-6
pubmed: 1376019
Diabetes Care. 2010 Nov;33(11):2399-405
pubmed: 20980427
Indian J Ophthalmol. 2020 Jan;68(1):145-151
pubmed: 31856493
Lasers Med Sci. 2019 Jul;34(5):907-912
pubmed: 30368640
Br J Ophthalmol. 2005 Jul;89(7):864-70
pubmed: 15965168
Ophthalmologica. 2017;237(4):185-222
pubmed: 28423385
Retina. 2020 Feb;40(2):312-321
pubmed: 31972802
J Clin Med. 2021 Mar 31;10(7):
pubmed: 33807216
Ophthalmology. 2019 Jan;126(1):87-95
pubmed: 30096354
Curr Diabetes Rev. 2012 Jul 1;8(4):274-84
pubmed: 22587512
Eur J Ophthalmol. 2018 Jan;28(1):68-73
pubmed: 28731494
Retina. 2020 Jan;40(1):126-134
pubmed: 30300267
Retina. 2016 Nov;36(11):2059-2065
pubmed: 27096529
Int Ophthalmol. 2020 May;40(5):1147-1154
pubmed: 31919773
N Engl J Med. 2015 Mar 26;372(13):1193-203
pubmed: 25692915
Transl Vis Sci Technol. 2020 Aug 07;9(9):15
pubmed: 32879771
Semin Ophthalmol. 2001 Mar;16(1):8-11
pubmed: 15487692
Ophthalmology. 2011 Apr;118(4):615-25
pubmed: 21459215